Relatlimab
- Generic Name
- Relatlimab
- Brand Names
- Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1673516-98-7
- Unique Ingredient Identifier
- AF75XOF6W3
- Background
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint inhibit...
- Indication
Relatlimab is indicated in combination with nivolumab, in the combination product Opdualag, for the treatment of adult and pediatric patients β₯12 years old with unresectable or metastatic melanoma.
- Associated Conditions
- Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT03310619
- Locations
- πΊπΈ
Local Institution - 015, Omaha, Nebraska, United States
πΊπΈLocal Institution - 016, Philadelphia, Pennsylvania, United States
πΊπΈLocal Institution - 011, Duarte, California, United States
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2024-01-16
- Target Recruit Count
- 32
- Registration Number
- NCT03044613
- Locations
- πΊπΈ
Johns Hopkins University, Baltimore, Maryland, United States
πΊπΈAlleghany Health Network, Pittsburgh, Pennsylvania, United States
πΊπΈBaylor University/ Charles A. Sammons Cancer Center, Dallas, Texas, United States
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT02966548
- Locations
- π―π΅
Local Institution - 0001, Kashiwa-shi, Chiba, Japan
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 578
- Registration Number
- NCT02488759
- Locations
- πΊπΈ
Local Institution - 0003, Atlanta, Georgia, United States
π§πͺLocal Institution - 0012, Brussels, Belgium
πΊπΈLocal Institution - 0033, Tampa, Florida, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Interventions
- Drug: AfatinibDrug: CapivasertibDrug: BinimetinibDrug: AdavosertibProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: Afatinib DimaleateDrug: DabrafenibDrug: DefactinibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: TaselisibDrug: SapanisertibDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: UlixertinibBiological: Trastuzumab EmtansineDrug: Copanlisib HydrochlorideBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabDrug: Larotrectinib SulfateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- πΊπΈ
Alaska Women's Cancer Care, Anchorage, Alaska, United States
πΊπΈAnchorage Oncology Centre, Anchorage, Alaska, United States
πΊπΈKatmai Oncology Group, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.